reports were reviewed daily, analysed and input into the French Pharmacovigilance database. AEs were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) [3] . An AE was considered "serious" if it was life threatening or resulted in death, permanent disability, congenital anomaly, hospitalization or prolonged hospitalisation [4] . An event was ranked "medically serious" when it requires medical intervention or hospitalisation <24 h to prevent one of the outcomes listed in the serious AE definition [4] . Particular attention was given to AEs of special interest (AESIs) as defined by EMA [5] , mainly demyelinating disorders and GuillainBarré syndrome (GBS). GBS was defined according to Asbury criteria [6] , and multiple sclerosis (MS) was defined following McDonald's criteria [7] . Data reported in our study does not include AEs in pregnant women.
During the campaign, 4.1 million doses of Pandemrix® and 1.6 million doses of Panenza® were administered (French Health Authorities data). Among the 4,746 declarations received (Pandemrix® plus Panenza®), 3, 740 (78.8%) came from health practitioners and 1,006 (21.2%) from patients. Following Pandemrix®, 4,180 AEs were reported (reporting rate102 :100,000 vaccine doses) including 334 "medically serious" and 193 "serious". The main "nonserious" AEs were "general and local disorders" (65.9%, mainly influenza-like illness, pain and site reactions) followed by "neurological disorders" (17.6%, mainly paresthesia and headaches). Concerning Panenza®, 566 AEs were reported (reporting rate35:100,000), including 61 "medically serious" and 70 "serious". The main "nonserious" AEs were "general and local disorders" (47.0%, mainly influenza-like illness, pain and malaises) and "allergic reactions" (16.3%, mainly cutaneous reactions). The most frequently reported "serious" AEs were neurological for both Pandemrix® (38.9%) and Panenza® (28.9%). Isolated ascending paresthesia (without any other neurological symptom and complication) were the most frequent AEs, with Pandemrix® in adults, and febrile convulsions being the most common neurological AEs with Panenza® in children ( Table 1) . The table shows the most common "serious", "non serious" and "medically serious" AEs, as well as three AEs of special interest (AESIs): seizures, Guillain-Barré syndrome and demyelinating disorders. Values are number of reports. For each AE, value between brackets indicates percentage of AE concerned according to the "seriousness".
(a) Using MedDRA terms. More than 1 code could be assigned to a single report. (e) Seizures term includes febrile convulsion, epileptic seizure and status epilepticus.
(f) Demyelinating disorders term includes multiple sclerosis relapse and primary multiple sclerosis.
(g) Gastrointestinal disorders term includes nausea, abdominal pain, vomiting and diarrhoea.
(h) Hypersensitivity reactions term includes anaphylactic shock, hypersensitivity, urticaria, angioedema.
Among the 75 AESIs, 13 GB cases were reported, with a delay of 4 days to 4 months after vaccination. Eight of these 13 patients had a viral infection during the weeks before. Fifteen cases of demyelinating disorders occurred from 1 to 61 days after injection. Seven of these 15 patients suffered from MS relapse, whereas the other eight occurred in patients without any history of MS. In all reported deaths (n=22) causes other than recent A(H1N1)v vaccination were described. No report of narcolepsy was made during the study period. Cases with cataplexy or narcolepsy were been reported later -from August 2010 forward.
This review summarises surveillance data from 5.7 millions doses of vaccine administered in France. For the first time, patient reporting was formally introduced in France, reaching 21.2% of the collected reports. Most reports were considered "nonserious". Injection site reactions appeared to be more frequent with the adjuvant vaccine and allergic AE with the nonadjubant vaccine. For both types of vaccine, neurological AEs were among the most frequently reported "serious" AEs, with 13 reports of confirmed GBS and 15 reports of demyelinating disorders. However, no causal relationship has been established between these AEs and vaccination. Finally, despite limits of this survey based on spontaneous reporting (especially underreporting, which remains difficult to quantify [1] and background rates of diseases [8] ), the study did not detect any safety issues, at least within the 8-month follow-up.
